Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

tation, and 3 were EGFR wild-type.

-- All 6 patients with EGFR-activating mutations demonstrated clinical

benefit (5 PR, 1 SD).

-- XL647 is generally well tolerated in this patient population. The most

frequently reported adverse events assessed as being related to XL647

were diarrhea, rash, fatigue, and nausea, all of which were Grade 1 or

Grade 2 in severity.

"The data reported today demonstrate that XL647 has potential utility in patient populations with both mutated and wild-type EGFR," said Dr. Shirish Gadgeel of Karmanos Cancer Institute at Wayne State University. "Importantly, the data highlight that patients to date appear to have milder EGFR-related side-effects -- rash and diarrhea -- than previously described with other EGFR inhibitors while retaining potent anti-tumor activity with durable responses and stable disease. Although these are early results, they provide a compelling rationale for expediting the full development of XL647 in non-small cell lung cancer."

"These data suggest that XL647 has the potential for utility in patients with NSCLC who have an activating EGFR mutation and those with wild-type EGFRs. We believe these data support an aggressive clinical development strategy in first, second and third-line treatment as both a single agent and in combination with other therapies," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Moreover, new data from an ongoing phase 1 trial of XL647 suggest that daily dosing results in higher drug concentrations than those observed to date in this phase 2 study with intermittent dosing. We expect to complete this evaluation of both daily and intermittent dosing schedules soon in order to select the optimal regimen and dose for the late-stage development of XL647."

The most frequently reported treatment-related adverse events (AEs) were Grade 1 and 2 diarrhea and fatigue, and Grade 1 nausea and rash. Six pat
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... October 24, 2014 SonaCare Medical, ... ultrasound (HIFU) technology, announced that its Board of ... Chief Executive Officer, President and member of the ... Carol will take-on expanded responsibilities within the company, ... well as overseeing commercialization, manufacturing and finance. ...
(Date:10/25/2014)... ROCKVILLE, Md. , Oct. 24, 2014  RegeneRx Biopharmaceuticals, ... on data presented at the Fourth International Symposium on ... , Italy.  "When thymosin beta ... was injected into the peritoneal cavity in a rodent ... vessels and throughout the brain parenchyma (the functional tissue ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
(Date:10/22/2014)... Involution Studios , a healthcare software ... infographic, Understanding Ebola . The goal of ... to follow informative tool for anyone wanting to know ... prevention. , "As the news has spread in all ... represents not only a healthcare crisis with global impact, ...
Breaking Biology Technology:SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2
... THE WOODLANDS, Texas, September 1 Berlin Heart Inc.,reported ... the Berlin,Heart EXCOR(R) Pediatric IDE Study after having received unconditional,approval ... The Principal Investigator, Dr. Charles Fraser, ... of Surgery and Pediatrics,at Baylor College of Medicine ...
... , , ST. LOUIS and ... MON ) today announced a non-exclusive research and commercial license agreement ... genome engineering, for broad use of its meganuclease technology in plants. ... be directed to a single site in the genome of a ...
... HARBIN, China, Sept. 1 /PRNewswire-Asia-FirstCall/ -- China Kangtai ... integrated grower,developer, manufacturer and marketer of a variety ... company has successfully completed the trial,production of cactus-based ... the,forth quarter in 2009: (i) low nicotine and ...
Cached Biology Technology:Major Milestone Achieved - Berlin Heart EXCOR Pediatric IDE Study 2Monsanto Licenses Use of Cellectis' Innovative Genome Modification Technology 2Monsanto Licenses Use of Cellectis' Innovative Genome Modification Technology 3China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes 2China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes 3
(Date:10/22/2014)... Oct. 21, 2014 Aware, Inc. (NASDAQ: ... today reported financial results for its third quarter ended September ... 2014 was $6.0 million, an increase of 40% compared to ... in the third quarter of 2014 was $4.1 million compared ... operating income in the current three month period was primarily ...
(Date:10/18/2014)... of patients with undiagnosed, suspected genetic conditions, a certain ... higher molecular diagnostic yield than traditional molecular diagnostic methods, ... The study is being released to coincide with the ... sequencing, which sequences the protein­coding region of the genome ... in a cell or organism), has been rapidly applied ...
(Date:10/17/2014)... German . ... When treating overdoses, doctors are often limited to supportive therapy ... is a combination of drugs involved. So what can be ... grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute of ... to this question. "The task was to develop an agent ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3
... Direction Chocolate Chip Cookies TM lower cholesterol and ... disease, according to a published study in The Journal ... with a combination of psyllium and plant sterols, are ... with cholesterol. , The American Heart Association estimates ...
... than boots, a screen and a bucket, scientists studying a ... biomass in Tampa Bay now say they have found the ... the development of the modern-day human immune system. , The ... system protein that is similar to but much hardier than ...
... everything of importance in biology. The genome rules all of ... that among the diverse forms of RNA, a kind of ... and with genes directly to manage the genome from behind ... the vast stretches of DNA that do not code for ...
Cached Biology News:New study finds chocolate chip cookies lower cholesterol 2Tiny Tampa Bay fish key to evolution of immune system 2Tiny Tampa Bay fish key to evolution of immune system 3Peering into the shadow world of RNA 2Peering into the shadow world of RNA 3
The Holten Safe 2010 Class II Biological Safety Cabinets provide the most ergonomical working condition of comfort while incorporating the latest technology for safety, efficiency and performance....
... is designed with a variety of motion ... all in one unit. Shake, rock, roll ... compartments allow for hybridization and blotting procedures ... , The upper chamber uses a roller ...
... Magnetic Stand-96 is designed for paramagnetic bead ... 0.2 ml PCR plates with no additional ... base in a standard SBS 96-well microplate ... permanent magnets guarantees easy and fast (as ...
... magnetic particle based purification systems provide high ... any sample. They offer increased throughput and ... systems- KingFisher, KingFisher mL and KingFisher 96, ... l. Each system consists of an instrument, ...
Biology Products: